Benjamin Friedmann, Global Product Leader, Oncology at AstraZeneca, shared on LinkedIn:
“After decades of research into HER2, it’s remarkable to reflect on how far the science has evolved and how much we are still learning.
In breast cancer, HER2 established a new model for biomarker-led cancer care, showing how understanding tumour biology can help guide clinical decision-making. Today, science is revealing an increasingly nuanced picture of HER2, from different levels of expression to its relevance across multiple tumour types.
That’s one of the things I find most exciting about oncology: science doesn’t stand still. As our understanding deepens, new possibilities emerge for people living with cancer.
Rushee Jolly and I explore the evolving story of HER2, and where the science could take us next, in our latest AstraZeneca What Science Can Do article.”
You can also read: HER2-Positive Breast Cancer in 2026: The New Goal Is Not More Treatment, but the Right Treatment.
